GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SymBio Pharmaceuticals Ltd (TSE:4582) » Definitions » Cyclically Adjusted Revenue per Share

SymBio Pharmaceuticals (TSE:4582) Cyclically Adjusted Revenue per Share : 円217.08 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

SymBio Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2024 was 円13.867. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円217.08 for the trailing ten years ended in Mar. 2024.

During the past 12 months, SymBio Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -46.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of SymBio Pharmaceuticals was -46.70% per year. The lowest was -47.90% per year. And the median was -47.30% per year.

As of today (2024-06-09), SymBio Pharmaceuticals's current stock price is 円155.00. SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was 円217.08. SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SymBio Pharmaceuticals was 9.30. The lowest was 0.16. And the median was 1.68.


SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

SymBio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,602.64 1,433.87 237.01 227.11 217.41

SymBio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 221.54 221.14 216.46 217.41 217.08

Competitive Comparison of SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, SymBio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=13.867/107.2000*107.2000
=13.867

Current CPI (Mar. 2024) = 107.2000.

SymBio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 104.670 98.000 114.496
201409 48.543 98.500 52.831
201412 74.935 97.900 82.053
201503 50.410 97.900 55.199
201506 70.137 98.400 76.409
201509 43.985 98.500 47.870
201512 74.198 98.100 81.081
201603 23.856 97.900 26.122
201606 98.790 98.100 107.954
201609 17.323 98.000 18.949
201612 82.567 98.400 89.951
201703 72.323 98.100 79.032
201706 74.832 98.500 81.442
201709 49.777 98.800 54.009
201712 76.050 99.400 82.018
201803 62.092 99.200 67.099
201806 66.728 99.200 72.109
201809 57.601 99.900 61.810
201812 38.989 99.700 41.922
201903 78.154 99.700 84.033
201906 16.152 99.800 17.350
201909 0.126 100.100 0.135
201912 31.410 100.500 33.504
202003 19.917 100.300 21.287
202006 23.018 99.900 24.700
202009 27.613 99.900 29.631
202012 17.144 99.300 18.508
202103 37.198 99.900 39.916
202106 44.952 99.500 48.431
202109 62.642 100.100 67.085
202112 69.590 100.100 74.526
202203 59.330 101.100 62.910
202206 65.216 101.800 68.675
202209 61.871 103.100 64.331
202212 66.190 104.100 68.161
202303 39.080 104.400 40.128
202306 41.098 105.200 41.879
202309 31.240 106.200 31.534
202312 27.699 106.800 27.803
202403 13.867 107.200 13.867

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


SymBio Pharmaceuticals  (TSE:4582) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SymBio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=155.00/217.08
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of SymBio Pharmaceuticals was 9.30. The lowest was 0.16. And the median was 1.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


SymBio Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of SymBio Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SymBio Pharmaceuticals (TSE:4582) Business Description

Traded in Other Exchanges
Address
5-23-7 Shimbashi, San-Ei Building, 8th Floor, Minato-ku, Tokyo, JPN, 105-0004
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in manufacturing and commercializing drugs for oncology, hematology, and pain management.

SymBio Pharmaceuticals (TSE:4582) Headlines

No Headlines